Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.

Gonzalez-Rodriguez, E.; Aubry-Rozier, B.; Stoll, D.; Lamy, O.

doi:10.1002/art.41016

Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.

Details

Request a copy

Serval ID

serval:BIB_F90DC7040A4D

Type

Article: article from journal or magazin.

Publication sub-type

Letter (letter): Communication to the publisher.

Collection

Publications

Institution

UNIL/CHUV

Title

Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.

Journal

Arthritis & rheumatology

Author(s)

Gonzalez-Rodriguez E., Aubry-Rozier B., Stoll D., Lamy O.

ISSN

2326-5205 (Electronic)

ISSN-L

2326-5191

Publication state

Published

Issued date

10/2019

Peer-reviewed

Oui

Volume

Number

Pages

1770-1771

Language

english

Notes

Publication types: Letter ; Comment
Publication Status: ppublish

Abstract

We read with interest the Article by KG. Saag and colleagues (1). This 24-month randomised trial demonstrated the efficacy and safety of denosumab compared with risedronate. The discussion does not take into account three major concerns regarding denosumab discontinuation (DD) that could modify the conclusions. This article is protected by copyright. All rights reserved.

Keywords

Bone Density Conservation Agents, Denosumab, Diphosphonates, Double-Blind Method, Glucocorticoids, Humans, Osteoporosis, Risedronic Acid

OAI-PMH

oai:serval.unil.ch:BIB_F90DC7040A4D

DOI

10.1002/art.41016

Pubmed

31215777

Web of science

000484426600001

Create date

24/06/2019 17:09